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A partial pathway- and network-based
transformation reveals the synergistic
mechanism of JA and UA against cerebral
ischemia-reperfusion injury
Dear Editor,
Ischemic stroke falls under the category of complex dis-
eases, which do not obey the single-gene dominant or sin-
gle-gene recessive Mendelian pattern of inheritance but
rather arises from the combination of numerous genetic
variants and environmental factors (Cho et al., 2012). Given
this degree of complexity, a single compound could never be
expected to manage or reverse the effects of a stroke.
Recently there has been accumulating evidence suggesting
that combination therapies could exert a signiﬁcant effect on
areas affected by a cerebral ischemic stroke. Combination
therapies that simultaneously impact multiple targets have
promise in the control of complex diseases by way of syn-
ergy (Li et al., 2011).
Jasminoidin (JA) and ursodeoxycholic acid (UA) are
compounds extracted from Qingkailing injection, which was
extensively used for treating acute ischemia stroke for dec-
ades in China (Cheng et al., 2012). There was synergistic
effect observed with the combination of JA and UA with
regard to the reduction of infarction volumes, a decrease in
the neurological deﬁcit score and the MRI results in ischemic
rats (Liu et al., 2012). However, till now, little was known
regarding the synergistic mechanism of JA and UA in the
treatment of ischemia stroke until the implementation of an
integrated network analysis of global gene expression
proﬁling.
In the present study, we aim to investigate the synergistic
mechanism of JA and UA against cerebral ischemia on a
systemic level. The IPA system was applied to identify the
differential networks and canonical pathways as well as to
determine the overlap of these diverse biological functions
using an integrated network analysis of the global gene
expression proﬁling in the JA, UA, JU (JA + UA combination)
treatment groups.
Firstly, the IPA results revealed 11 statistically signiﬁcant
networks between the JU and vehicle groups. The top 5
networks included 35, 35, 35, 34 and 35 nodes (genes;
proteins) (Table.S1). Network 1 includes gene expression,
cell cycle and cellular compromise (Fig. 1A); network 2
functions in DNA replication, recombination and repair, drug
metabolism, and endocrine system development and func-
tion (Fig. 1B); network 3 involves endocrine system devel-
opment and function, small molecule biochemistry, and
organ morphology (Fig. 1C); network 4 includes cell death,
neurological disease, and connective tissue disorders
(Fig. 1D); and network 5 functions in lipid metabolism,
molecular transport, and small molecule biochemistry
(Fig. S1).
Secondly, the IPA analysis also identiﬁed 33 statistically
signiﬁcant canonical pathways out of 149 pathways
involving the differentially expressed genes between the JU
and vehicle groups (Table.S2). Of these 33 canonical
pathways, the combination JU treatment regulated as many
as 13 pathways independently, including renin-angiotensin
signaling and cAMP-mediated signaling, whereas the JU,
JA and UA groups showed 6 overlapping pathways.
Meanwhile 6 overlapping pathways were identiﬁed between
the JA and JU groups, and 8 overlapping pathways were
discovered between the UA and JU groups (Fig. 2A). Fur-
thermore, 10 out of 13 non-overlapping pathways regulated
by JU separately were related to cerebral ischemia. These
pathways were largely related to inﬂammation, apoptosis/
necrosis, and neurogenesis/angiogenesis with regard to
cerebral ischemia. However, 6 non-overlapping pathways in
the JU group were stimulated by microglial activation,
which plays a key role in the inﬂammatory reaction during
cerebral ischemia (Fig. 2B). More importantly, 3 non-over-
lapping pathways were identiﬁed to be involved in cerebral
ischemia for the ﬁrst time, including molecular mechanisms
of cancer, PXR/RXR activation, and caveolar-mediated
endocytosis.
Thirdly, compared with the vehicle group, a total of 66
overlapping biological functions were identiﬁed among the
JA, UA and JU groups, which accounted for 79.52 % of all
the functions. Interestingly, 5 overlapping functions were
discovered between the JA and UA groups, one overlapping
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function (amino acid metabolism) was discovered between
the JA and JU groups, and 2 overlapping functions (gas-
trointestinal disease, renal and urological disease) were
discovered between the UA and JU groups. Meanwhile, a
total of 2, 4 and 3 unique functions were identiﬁed in the JA,





















































Note:“Acts on” and “inhibits” edges may also include a binding event.
Figure 1. Statistically signiﬁcant signaling pathway networks between JU and vehicle groups. Statistically signiﬁcant signaling
pathway networks involving the differentially expressed genes between JU and vehicle groups. (A) Network 1; (B) Network 2;
(C) Network 3; (D) Network 4. The red node denotes an up-regulated gene, and the green node denotes a down-regulated gene. The
intensity of colours indicates the degree of up-regulation or down-regulation.
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functions of the JU group are cell death, cancer, cell cycle,
cellular growth and proliferation, tissue morphology, DNA
replication, recombination and repair, small molecule bio-
chemistry, hematological disease, tissue development and
hepatic system disease (Fig. S3). Moreover, according to the
IPA analysis of the 66 overlapping functions among the JA,
UA and JU groups, 21 functions (31.82%) belong to the
category of diseases and disorders, 21 functions (31.82%)
are related to molecular and cellular functions, and 24
functions (36.36%) are involved in physiological system
development and function. The distribution of these func-
tions is shown as list (Fig. S4).
In our current study, based on the analysis of the top 5 dif-
ferential networks, 3 overlapping network functions were
identiﬁed in the JA, UA and JU groups, including cellular com-
promise, small molecule biochemistry and lipid metabolism.
These functions have been reported to be involved in cerebral
ischemia (Simao et al., 2013; Takeda et al., 2004; Zhan et al.,
2010). More importantly, we identiﬁed 6 non-overlapping net-
work functions in the JU group, including cell cycle, drug
metabolism, endocrine system development and function,
organ morphology, connective tissue disorders, and molecular
transport. Our results might suggest that the networks involved
in the JU-dependent effects signiﬁcantly vary from those of the
JA and UA treatments alone in conquering cerebral ischemia.
The transformed novel activation pathways maybe
involved in the synergistic mechanism of JA and UA, in
which 10 pathways were related to cerebral ischemia. Oxi-
dative stress plays a crucial role in brain damage after
stroke. During cerebral ischemia-reperfusion, signiﬁcant
amounts of oxygen free radicals are generated, and the
resting microglia in brain is activated and developed mac-
rophage-like abilities, including phagocytosis and inﬂam-
matory responses (Ekdahl et al., 2009). Additional evidence
demonstrates that microglia mediates inﬂammation by
secreting pro-inﬂammatory and anti-inﬂammatory cytokines
as well as triggering neuronal apoptosis or death in response
to ischemic injury. In our study, 3 unique pathways of pro-
inﬂammatory cytokines were identiﬁed in the JU group,
including IL-6 signaling, IL-17 signaling, and the LPS/IL-1
mediated inhibition of RXR function. It was reported that the
upregulated IL-6 and IL-1 may target the vascular endothe-
lium to mediate inﬂammatory cascades, resulting in the
aggravation of cerebral ischemic damage during the acute
phase (Jafarinaveh et al., 2014). The major downstream
signaling pathway of IL-6 is JAK-STAT, and STAT3 activation
primarily occurs in neurons during ischemic reperfusion
(Suzuki et al., 2009). STAT3 is a transcription factor that
binds to DNA in the nucleus and initiates the production of
more interleukins involved in the acute inﬂammatory
response. In the experimental ischemia-reperfusion (I/R)
brain model, IL-17 was veriﬁed to have pivotal roles in the
evolution of brain infarction and the delayed phase of I/R
injury. The induction of IL-17 was dependent on IL-23.
Therefore, the activation of the 3 inﬂammatory signaling
pathways may contribute to the synergistic mechanism of JA
and UA. However, 2 unique pathways of anti-inﬂammatory
cytokines were discovered in the JU group, including IL-10
signaling and IL-22 signaling. IL-10 and IL-22 are key
members of the IL-10 cytokine family, and previous studies
have highlighted the protective function of endogenous IL-10
and IL-22 during ischemic stroke through ameliorating brain
inﬂammation and injury (Fouda et al., 2013). Additionally,
IL-10 and IL-22 can directly provide protection to cortical
neurons by acting on STAT3 signal transduction pathways.
Traditionally, the renin-angiotensin system (RAS) has been
regarded as an endocrine system that was responsible for
long-term control of blood pressure, the development of
hypertensive cardiomyopathy, and the development and
progression of atherosclerosis. Presently, some studies have
shown that RAS enhances vascular inﬂammation through
cytokine-like actions and, through angiotensin II (AngII),
induces the expression of the pro-inﬂammatory cytokine IL-6
(Brasier et al., 2002). Our results are the ﬁrst instances of
evidence that both pro-inﬂammatory and anti-inﬂammatory
cytokines as well as RAS are involved in the synergistic
mechanism of JA and UA. Additionally, we identiﬁed 3 novel
pathways that were not originally related to cerebral ische-
mia, including molecular mechanisms of cancer, PXR/RXR
activation, and caveolar-mediated endocytosis. Further
investigations are necessary to determine the effect of these
signaling pathways on the progression of cerebral ischemia.
The biological effects of JU treatment differ greatly from
those of JA and UA treatment alone. Organismal survival,
psychological disorders, and protein synthesis were identiﬁed
as the transformed biological functions in the JU group. Previ-
ous studies demonstrated that transient cerebral ischemia
triggered the suppression of protein synthesis. The phosphor-
ylation of eukaryotic initiation factor 2α (eIF2α) and eukaryotic
translation initiation factor 4GI (eIF4GI) correlates with the
inhibition of protein synthesis and decreased viability at differ-
ent time points during reperfusion (DeGracia et al., 2002).
Either activated pERK or IREα phosphorylates eIF2α, which
then inhibits most protein synthesis and may be a defense
mechanism to ischemia-induced ER stress. However, the
persistence of p-eIF2α coupled with eIF4G degradation may
induce a pathological transition that results in a disproportion at
expression of proapoptotic genes due to residual translation
(Wek et al., 2006). To our knowledge, there is little evidence
showing that the biochemical functions of organismal survival
and psychological disorders were involved in cerebral ische-
mia. Further research is required to discover the correlation
between the disease and these functions.
In conclusion, our integrated network analysis revealed
that JA and UA treatments individually affected multiple
pathways, including IGF-1 signaling. However, combining
these two compounds produced a synergistic mechanism
that transformed several novel activation signaling path-
ways, including six inﬂammatory pathways and cAMP sig-
naling, as well as alteration of biological functions, such as
cell cycle, endocrine system development and function, and
protein synthesis.
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s Figure 2. Canonical pathways among different groups.
(A) The 33 statistically signiﬁcant canonical pathways between
JU and vehicle groups. The red histograms represented non-
overlapping pathways in JU group. The blue histograms
represented overlapping pathways among JA, UA and JU
groups. The grey, green histograms represented overlapping
pathways between JA and JU, UA and JU groups respectively.
(B) The proposed therapeutic targets of JU group on cerebral
ischemia-reperfusion injury. JU played differential roles in
schematic view of known pathways. The blue ellipses within
solid line represented unique canonical pathways in JU group;
blue and pink ellipses within solid line represented canonical
pathways in JA and JU group; blue and yellow ellipses within
solid line represented canonical pathways in UA and JU group;
blue, yellow and pink ellipses within solid line represented
canonical pathways in JA, UA and JU group. Blue ellipses
denote the potential therapeutic targets and synergistic mech-
anism of the combination of JA and UA.
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